Wave Life Sciences Q3 2022 net loss $39M; HD trial shows allele-selective mHTT reduction

Wave Life Sciences Ltd.

2022-Q3 EPS reported -$1.60 revenue$2,410,000

Net loss of $39.0M vs $6.2M in Q3 2021; revenue $0.3M down from $36.4M due to Takeda amendment.
SELECT-HD: WVE-003 reduced mHTT by mean 22% (median 30%) at 85 days post single dose; wtHTT preserved.
WVE-N531 multidosing underway in DMD; muscle biopsy data expected in 4Q 2022.
Selected WVE-006 as first RNA editing candidate for AATD; CTA submissions expected in 2023.
Cash $122.0M as of Sept 30, 2022; runway expected to fund operations to end of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Wave Life Sciences Ltd. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-22-281960

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.